Single-institute, retrospective study of metastatic uveal melanoma in the immune check point inhibitor era

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Melanoma
Presenter shiraishi kazuhiro
Citation Annals of Oncology (2018) 29 (suppl_9): ix105-ix108. 10.1093/annonc/mdy439
Authors S. kazuhiro1, K. Sugiyama1, K. Nozawa1, Y. Funahashi1, Y. Kogure1, C. Kitagawa1, S. Ichihara2, R. Nishimura2, T. Kubota3, H. Saka1
  • 1Medical Oncology, National Hospital Organization, Nagoya Medical Center, 460-0001 - Nagoya/JP
  • 2Pathology, National Hospital Organization, Nagoya Medical Center, 460-0001 - Nagoya/JP
  • 3Ophthalmology, National Hospital Organization, Nagoya Medical Center, 460-0001 - Nagoya/JP



Uveal melanoma is an extremely rare cancer. The outcomes of metastatic uveal melanoma (mUM) in the immune checkpoint inhibitor (ICI) era have not been clarified.


This study was designed as a single-institute, retrospective chart review. We reviewed 69 consecutive uveal melanoma patients between January 2002 and November 2017. The inclusion criteria were: pathologically/clinically confirmed uveal melanoma with distant metastasis, normal organ function, PS 0-1. The primary endpoint was overall survival (OS).


Eleven patients met the inclusion criteria. Median follow-up duration was 19.8 months (range 1-73). Patient characteristics were as follows: median age 60 years (range 43-79), six patients were treated with ICI (nivolumab, pembrolizumab, ipilimumab,) three patients were treated with chemotherapy, and two patients were treated with best supportive care. alone. Metastatic sites were the liver (64%), lung (18%), and lymph nodes (18%). Median time from initial treatment to recurrence was 48 months (95% CI, range 10-85). Median OS in the 11 patients was 30 months (95% CI, range 2-NA), and 5-year OS was 25%. The median OS in patients who received ICI and no ICI regimens was 40 months (95% CI, range 3-NA) and 10 months (95% CI, range 1-NA), respectively. The overall response rate and disease control rate in patients treated with ICI regimens were 16% and 50%, respectively. Treatment-related adverse events were reported in two patients, leading to treatment discontinuation in one patient. Grade ≥3 toxicities included fulminant type1 diabetes mellitus, colitis, and dermatitis. All the toxicities resolved with treatment.


OS in mUM patients treated with ICI showed a tendency to improve, with acceptable toxicities.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Kazuhiro Shiraishi.


Has not received any funding.


All authors have declared no conflicts of interest.